Bevacizumab was the first approved agent to inhibit tumor angiogenesis, in 2004 by the FDA and in 2005 in Europe. It is used in combination with other drugs such as 5-fluorouracil or irinotecan for the first-line treatment of patients with metastatic colorectal cancer, and is expected to be ...
Swirl the vial gently until the powder has dissolved entirely. Avoid shaking or rapid movement as it may cause foaming. The reconstituted XERAVA solution should be a clear, pale yellow to orange solution. Do not use the solution if you notice any particles or the solution is cloudy. Reconstit...